HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress Gives FDA Authority To Destroy Counterfeit Devices Found In Imports

Executive Summary

Safeguarding Therapeutics Act, approved by the House in September and by the Senate on 8 December, targets the proliferation of shipments into the US containing fake testing kits, cures and vaccines that claim to address coronavirus, some available OTC.

You may also be interested in...

US House Members Say FDA Should Destroy Fake Covid-19 Tests, Other Fraudulent Products It Finds

FDA's finding fraudulent Covid-19 test kits, but if they've been imported, say Energy and Commerce members, existing regulations preclude destroying the products. The committee says that “when these counterfeit medical devices, including tests, are imported [FDA] must either store it or ship it back.”

Senate Proposes Restoring Direct OTC Purchases With Pre-tax Savings In Covid-19 Response Bill

Tax-policy provision in Coronavirus Aid, Relief and Economic Security Act, which the Finance Committee calls Congress’ phase 3 coronavirus response, would change current language in Internal Revenue Service rules for HSAs, FSAs, Archer medical savings accounts and other health reimbursement arrangements to allow directly buying OTC drugs and would extend the categories of covered products to include tampons and other menstrual care products.

Bill To Allow FDA To Destroy Counterfeit Devices Wins Praise On Hill; J&J Exec Testifies In Support

Several US House members are backing a new piece of legislation that would give the US Food and Drug Administration the authority to destroy counterfeit devices when they arrive at points of entry into the country. A Johnson & Johnson executive who specializes in global brand protection provided dramatic testimony before a House health panel on 29 January on the need for the anti-counterfeiting bill.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts